Mr. Dunne: To ask the Secretary of State for Health (1) when Rosiglitazone is expected to be made available to patients most at risk of developing diabetes; [93260]
(2) what estimate she has made of the likely annual cost to the NHS of providing Rosiglitazone to those likely to benefit from it; [93261]
(3) what representations she has received about the estimated number of patients who would benefit from Rosiglitazone. [94046]
Ms Rosie Winterton: Rosiglitazone is not licensed for the prevention of type 2 diabetes.
No estimate has been made of the likely annual cost to the national health service of providing Rosiglitazone to those likely to benefit from it. However, the following data shows the current costs to the NHS for prescribing Rosiglitazone:
Net ingredient costs for the dispensing of glitazones | |||
Dispensing in the community | |||
£ | |||
| Pioglitazone | Metformin/Rosiglitazone | Rosiglitazone |
2005-06 | 15,794,860 | 13,420,190 | 46,822,312 |
| |||
Dispensing in hospitals | |||
£ | |||
| Pioglitazone | Metformin/Rosiglitazone | Rosiglitazone |
2005-06 | 255,752 | 34,939 | 607,218 |
The National Institute for Health and Clinical Excellence (NICE) published recommendations in 2003 on the use of glitazones for the treatment of type 2 diabetes. NICE is currently reviewing this guidance as part of a review of all of its type 2 diabetes guidance which is due to be published in February 2008.
I have received no representations about the estimated number of patients who would benefit from Rosiglitazone.
